May 1, 2019
One of the most exciting recent developments supported by the Michael J. Fox Foundation is the announcement of human trials of MCC950, a once daily pill therapy targeting the brain inflammation present in all PD patients that may stop Parkinson’s disease “in its tracks.” The progress of MCC950 is moving quickly with Phase 2 human...
Read More